Small Molecules and TPD World Series
The Small Molecules and TPD World Series is committed to delivering the most comprehensive collection of industry-dedicated forums, exclusively focusing on the specific challenges faced for each community of small molecules and protein degradation drug developers.
The goal for this event series is to provide your team with the platform to connect, learn and fast-track first-in-class or next generation of selective, orally bioavailable and clinically efficacious small molecules for undrugged or hard-to-drug targets to meet the needs of patients globally.
View the Small Molecules & TPD World Series conference calendar below. If you have any questions, get in touch at info@hansonwade.com.
Download the partnership prospectus to access key event information, audience breakdown, testimonials and partnership opportunities.
Successfully Screen & Validate Novel Protein-Protein Inducing Mechanisms & Chemical Matters to Improve the Selectivity & Off-Target Effect of Your Degrader & Non-Degrader Proximity-Based Drugs from Discovery to Clinic
July 23-25, 2024 | Boston, MA
Overcome Diverse Clinical Resistance Mechanisms with Emerging First- & Best-In-Class Combination & Monotherapies to Effectively Treat Patients with RAS-Driven Lung, Colorectal & Pancreatic Cancers
September 24-26, 2024 | Boston, MA
Fast-Track Discovery, Development & Approval of Selective, Safe & Clinically Relevant TACs & Glues for Degradation, Stabilization, & Phosphorylation to Successfully Address Unmet Need in Oncology & Beyond
October 29-31, 2024 | Boston, MA
Leverage Advances in Structural Biology, Screening & Target Validation Whilst Overcoming Pharmacology Challenges to Successfully Translate Your Small Molecules & Biologics from Novel Discoveries to Clinically Relevant & Effective GPCR Drugs
November 26-28, 2024 | London, UK
Improve Selectivity, Reduce Toxicity & Overcome Limitations of Preclinical Models & Clinical Biomarkers to Accelerate Translation & Development of Hippo Pathway Targeted Therapeutics for Patients
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond
December 10-12, 2024 | Boston, MA
Fast-Track Rational & Structure Based Molecular Glues from Discovery to Clinic by Improving PPI Prediction, Hit Discovery & Lead Optimization Whilst Overcoming PKPD & Toxicity Challenges to Finally Drug the Undruggable
Leverage Advances in Structural Biology, Screening & Target Validation Whilst Overcoming Pharmacology Challenges to Successfully Translate Your Small Molecules & Biologics from Novel Discoveries to Clinically Relevant & Effective GPCR Drugs
Returning March, 2025 | London, UK
Harnessing the Power of Advanced Computing, Genomic & Structure-Based Technologies to Safely & Selectively Target GPCRs with Next Generation Small Molecules & Biologics in Oncology, Metabolic Disorders & Beyond
Returning 2025 | Boston, MA